

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Paraneoplastic Diseases of the Central Nervous... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-167/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-167" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Paraneoplastic Diseases of the Central Nervous System" />
    
            <meta name="og:title" content="F1000Research Article: Paraneoplastic Diseases of the Central Nervous System.">
            <meta name="og:description" content="Read the latest article version by Jonathan Galli, John Greenlee, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="23466">
            <meta name="article-id" content="21309">
            <meta name="dc.title" content="Paraneoplastic Diseases of the Central Nervous System">
            <meta name="dc.description" content="Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient&rsquo;s clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor.">
            <meta name="dc.subject" content="neurological, paraneoplastic, antibody-mediated, immunotherapy">
            <meta name="dc.creator" content="Galli, Jonathan">
            <meta name="dc.creator" content="Greenlee, John">
            <meta name="dc.date" content="2020/03/06">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21309.1">
            <meta name="dc.source" content="F1000Research 2020 9:167">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="neurological">
            <meta name="prism.keyword" content="paraneoplastic">
            <meta name="prism.keyword" content="antibody-mediated">
            <meta name="prism.keyword" content="immunotherapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/03/06">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="167">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21309.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-167">
            <meta name="citation_title" content="Paraneoplastic Diseases of the Central Nervous System">
            <meta name="citation_abstract" content="Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient&rsquo;s clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor.">
            <meta name="citation_description" content="Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient&rsquo;s clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor.">
            <meta name="citation_keywords" content="neurological, paraneoplastic, antibody-mediated, immunotherapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jonathan Galli">
            <meta name="citation_author_institution" content="Department of Neurology, University of Utah, Salt Lake City, UT, 84108, USA">
            <meta name="citation_author_institution" content="2. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, 84148, USA">
            <meta name="citation_author" content="John Greenlee">
            <meta name="citation_author_institution" content="Department of Neurology, University of Utah, Salt Lake City, UT, 84108, USA">
            <meta name="citation_publication_date" content="2020/03/06">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="167">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21309.1">
            <meta name="citation_firstpage" content="167">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-167/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-167.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=23466 /> <input type=hidden id=articleId name=articleId value=21309 /> <input type=hidden id=xmlUrl value="/articles/9-167/v1/xml"/> <input type=hidden id=xmlFileName value="-9-167-v1.xml"> <input type=hidden id=article_uuid value=fdc30eb4-44b8-4e09-8897-39dbb14573df /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Paraneoplastic Diseases of the Central Nervous System"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21309.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21309.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-167"
  },
  "headline": "Paraneoplastic Diseases of the Central Nervous System",
  "datePublished": "2020-03-06T16:32:59",
  "dateModified": "2020-03-06T16:32:59",
  "author": [
    {
      "@type": "Person",
      "name": "Jonathan Galli"
    },    {
      "@type": "Person",
      "name": "John Greenlee"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient&rsquo;s clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-167",
            "name": "Paraneoplastic Diseases of the Central Nervous System"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Paraneoplastic Diseases of the Central Nervous System </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=23466 data-id=21309 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21309.1" data-recommended="" data-doi="10.12688/f1000research.21309.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-167/v1/pdf?article_uuid=fdc30eb4-44b8-4e09-8897-39dbb14573df" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21309-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21309-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21309-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Galli J and Greenlee J. Paraneoplastic Diseases of the Central Nervous System [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):167 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21309.1" target=_blank>https://doi.org/10.12688/f1000research.21309.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21309-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21309 id=track-article-signin-21309 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21309?target=/articles/9-167">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23466 /> <input name=articleId type=hidden value=21309 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Paraneoplastic Diseases of the Central Nervous System</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jonathan Galli<a href="https://orcid.org/0000-0002-7715-4302" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7715-4302</div><sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:john.greenlee@hsc.utah.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>John Greenlee</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jonathan Galli<a href="http://orcid.org/0000-0002-7715-4302" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7715-4302</div><sup>1,2</sup>,&nbsp;</span><span class=""><a href="mailto:john.greenlee@hsc.utah.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>John Greenlee</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 06 Mar 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21309.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Neurology, University of Utah, Salt Lake City, UT, 84108, USA<br/> <sup>2</sup> 2. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, 84148, USA<br/> <p> <div class=margin-bottom> Jonathan Galli <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> John Greenlee <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=64849-60817></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=64848-60816></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Paraneoplastic neurological syndromes are nonmetastatic complications of malignancy secondary to immune-mediated neuronal dysfunction or death. Pathogenesis may occur from cell surface binding of antineuronal antibodies leading to dysfunction of the target protein, or from antibodies binding against intracellular antigens which ultimately leads to cell death. There are several classical neurological paraneoplastic phenotypes including subacute cerebellar degeneration, limbic encephalitis, encephalomyelitis, and dorsal sensory neuropathy. The patient’s clinical presentations may be suggestive to the treating clinician as to the specific underlying paraneoplastic antibody. Specific antibodies often correlate with the specific underlying tumor type, and malignancy screening is essential in all patients with paraneoplastic neurological disease. Prompt initiation of immunotherapy is essential in the treatment of patients with paraneoplastic neurological disease, often more effective in cell surface antibodies in comparison to intracellular antibodies, as is removal of the underlying tumor. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> neurological, paraneoplastic, antibody-mediated, immunotherapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> John Greenlee (<a href="mailto:john.greenlee@hsc.utah.edu">john.greenlee@hsc.utah.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> John Greenlee </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This research was supported by a Merit Review award from the US Department of Veterans Affairs (JEG). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Galli J and Greenlee J. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Galli J and Greenlee J. Paraneoplastic Diseases of the Central Nervous System [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):167 (<a href="https://doi.org/10.12688/f1000research.21309.1" target=_blank>https://doi.org/10.12688/f1000research.21309.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 06 Mar 2020, <b>9</b>(F1000 Faculty Rev):167 (<a href="https://doi.org/10.12688/f1000research.21309.1" target=_blank>https://doi.org/10.12688/f1000research.21309.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 06 Mar 2020, <b>9</b>(F1000 Faculty Rev):167 (<a href="https://doi.org/10.12688/f1000research.21309.1" target=_blank>https://doi.org/10.12688/f1000research.21309.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d6625e157>Introduction</h2><p class="" id=d6625e160>Paraneoplastic neurological syndromes are non-metastatic complications of systemic malignancy, in which clinical syndromes are the result of immune-mediated neuronal dysfunction or death. The syndromes may have their onset as long as five years prior to detection of the associated malignancy, during treatment, or (less often) when the underlying malignancy is in remission. The syndromes occur when the underlying neoplasm expresses proteins that are cross-reactive with neuronal antigens<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. Paraneoplastic neurological syndromes are thus among the few autoimmune conditions in which the immune targets that initiate the disease are known. In this review, we concentrate predominantly on paraneoplastic neurological syndromes affecting the central nervous system (CNS) or sensory ganglia; syndromes affecting the myoneuronal junction or peripheral nerves will not be discussed. The article will discuss current concepts of pathogenesis, clinical features of the major paraneoplastic syndromes, and approaches to treatment.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6625e173>Pathogenesis</h2><p class="" id=d6625e176>That paraneoplastic neurological injury could have an autoimmune basis was suggested by Wilkinson and Zebrowski in the 1960s<sup><a href="#ref-5">5</a></sup> and Trotter <i>et al</i>. in the 1970s<sup><a href="#ref-6">6</a></sup>. A definitive association of autoimmunity in paraneoplastic neurological disease came through work by Greenlee and Brashear<sup><a href="#ref-7">7</a></sup> and Jaeckle <i>et al</i>.<sup><a href="#ref-8">8</a></sup>, who demonstrated antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration. Over the ensuing years, many other patterns of antibody response have been associated with neurological disease in the presence of other systemic cancers (<a href="#T1">Table 1</a> and <a href="#T2">Table 2</a>), and it is now recognized that paraneoplastic neurological syndromes may be accompanied by two separate patterns of immune response: syndromes in which the immune response is directed against neuronal receptors or other cell membrane antigens and syndromes in which immunoreactivity is directed against intracellular neuronal proteins. The former group of syndromes are characterized by neuronal dysfunction, may or may not be associated with underlying neoplasia, and are frequently amenable to treatment. Syndromes in the latter group—those in which the immune response targets intracellular antigens—are almost always found in the presence of cancer and are characterized by neuronal death. Neurological deficits in these conditions, once intrinsic neuronal reserve has been exhausted, are irreversible.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Major paraneoplastic antineuronal antibodies reactive with neuronal membrane antigens.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6625e219 class=n-a></a><thead><a name=d6625e221 class=n-a></a><tr><a name=d6625e223 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e225 class=n-a></a>Antibody</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e228 class=n-a></a>Common neurological<br class=br>phenotypes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e233 class=n-a></a>Common associated<br class=br>malignancies</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e238 class=n-a></a>Frequency of<br class=br>underlying<br class=br>malignancy</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e245 class=n-a></a>Response to<br class=br>treatment<sup><a href="#FN1">a</a></sup></th></tr></thead><tbody><a name=d6625e255 class=n-a></a><tr><a name=d6625e257 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e259 class=n-a></a>Anti-AMPAR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e262 class=n-a></a>Limbic encephalitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e265 class=n-a></a>Breast<br class=br>Lung<br class=br>Thymus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e272 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e275 class=n-a></a>Good in many<br class=br>but not all<br class=br>patients</td></tr><tr><a name=d6625e283 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e285 class=n-a></a>Anti-LGI1/Anti-<br class=br>CASPR2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e290 class=n-a></a>Limbic encephalitis<br class=br>Faciobrachial dystonic<br class=br>seizures<br class=br>Morvan’s syndrome</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e299 class=n-a></a>Thymoma (especially in patients<br class=br>positive for both antibodies)<br class=br>Other neoplasms (rare)</td><td colspan=1 rowspan=1><a name=d6625e306 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e308 class=n-a></a>Usually poor </td></tr><tr><a name=d6625e312 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e314 class=n-a></a>Anti-GABAbR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e317 class=n-a></a>Limbic encephalitis,<br class=br>status epilepticus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e322 class=n-a></a>Small-cell lung cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e325 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e328 class=n-a></a>Poor</td></tr><tr><a name=d6625e332 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e334 class=n-a></a>Anti-mGluR1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e337 class=n-a></a>Cerebellar degeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e340 class=n-a></a>Hodgkin’s disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e343 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e346 class=n-a></a>Good</td></tr><tr><a name=d6625e350 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e352 class=n-a></a>Anti-mGlur2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e355 class=n-a></a>Cerebellar degeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e358 class=n-a></a>Small-cell cancer; alveolar<br class=br>rhabdomyosarcoma </td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e363 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e366 class=n-a></a>Variable</td></tr><tr><a name=d6625e371 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e373 class=n-a></a>Anti-mGluR5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e376 class=n-a></a>Limbic encephalitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e379 class=n-a></a>Hodgkin’s disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e382 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e385 class=n-a></a>Good</td></tr><tr><a name=d6625e389 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e391 class=n-a></a>Anti-VGKC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e394 class=n-a></a>Cerebellar degeneration<br class=br>(Lambert–Eaton<br class=br>myasthenic syndrome)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e401 class=n-a></a>Small-cell lung cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e404 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e407 class=n-a></a>Good in some<br class=br>patients</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6625e417 class=n-a></a><p id=FN1> Modified from <a href="#ref-13">13</a>. <sup>a</sup>Treatment involves both immunosuppressive treatment directed against the autoimmune process and treatment of the underlying malignancy.</p></div></div></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Major paraneoplastic antineuronal antibodies reactive with intracellular neuronal antigen.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d6625e442 class=n-a></a><thead><a name=d6625e444 class=n-a></a><tr><a name=d6625e446 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e448 class=n-a></a>Antibody</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e451 class=n-a></a>Common neurological<br class=br>phenotypes</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e456 class=n-a></a>Common associated<br class=br>malignancies</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e461 class=n-a></a>Frequency of<br class=br>underlying<br class=br>malignancy</th><th align=left colspan=1 rowspan=1 valign=top><a name=d6625e468 class=n-a></a>Response to<br class=br>treatment<sup><a href="#FN2">a</a></sup></th></tr></thead><tbody><a name=d6625e478 class=n-a></a><tr><a name=d6625e480 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e482 class=n-a></a>Anti-CRMP5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e485 class=n-a></a>Optic neuritis<br class=br>Cerebellar degeneration<br class=br>Encephalomyelitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e492 class=n-a></a>Small-cell lung cancer<br class=br>Breast carcinoma</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e497 class=n-a></a>Common</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e500 class=n-a></a>Poor</td></tr><tr><a name=d6625e504 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e506 class=n-a></a>Anti-GAD65</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e509 class=n-a></a>Stiff person syndrome<br class=br>Limbic encephalitis<br class=br>Cerebellar ataxia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e516 class=n-a></a>Thymoma<br class=br>Renal cell carcinoma<br class=br> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e523 class=n-a></a>Uncommon</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e526 class=n-a></a>Good in stiff<br class=br>person syndrome;<br class=br>otherwise poor</td></tr><tr><a name=d6625e534 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e536 class=n-a></a>Anti-Hu<br class=br>(ANNA-1)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e541 class=n-a></a>Limbic encephalitis,<br class=br>encephalomyelitis, dorsal<br class=br>sensory neuropathy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e548 class=n-a></a>Small-cell lung cancer<br class=br>Neuroendocrine tumors<br class=br>Retinoblastoma (infants)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e555 class=n-a></a>Almost invariable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e558 class=n-a></a>Poor</td></tr><tr><a name=d6625e562 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e564 class=n-a></a>Anti-Ma1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e567 class=n-a></a>Limbic or brain-stem<br class=br>encephalitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e572 class=n-a></a>Non-small-cell lung<br class=br>cancer; other</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e577 class=n-a></a>Almost invariable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e580 class=n-a></a>Poor</td></tr><tr><a name=d6625e584 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e586 class=n-a></a>Anti-Ma2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e589 class=n-a></a>Limbic or brain-stem<br class=br>encephalitis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e594 class=n-a></a>Testicular or other germ<br class=br>cell tumors<br class=br>Non-small-cell lung<br class=br>cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e603 class=n-a></a>Almost invariable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e606 class=n-a></a>Good if testicular<br class=br>neoplasm detected<br class=br>and treated</td></tr><tr><a name=d6625e615 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e617 class=n-a></a>Anti-Ri<br class=br>(ANNA-2)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e622 class=n-a></a>Cerebellar degeneration,<br class=br>opsoclonus myoclonus,<br class=br>brain-stem encephalitis </td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e629 class=n-a></a>Breast<br class=br>Small-cell lung cancer</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e634 class=n-a></a>Almost invariable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e637 class=n-a></a>Stabilization in<br class=br>some but not all<br class=br>patients</td></tr><tr><a name=d6625e645 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e647 class=n-a></a>Anti-Tr</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e650 class=n-a></a>Cerebellar degeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e653 class=n-a></a>Hodgkin’s disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e656 class=n-a></a>Almost invariable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e659 class=n-a></a>Poor</td></tr><tr><a name=d6625e663 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e665 class=n-a></a>Anti-Yo<br class=br>(PCA-1)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e670 class=n-a></a>Cerebellar degeneration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e673 class=n-a></a>Ovary, uterus, adnexa<br class=br>Breast</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e678 class=n-a></a>Almost invariable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d6625e681 class=n-a></a>Poor</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d6625e689 class=n-a></a><p id=FN2> Modified from <a href="#ref-13">13</a>. <sup>a</sup>Treatment involves both immunosuppressive treatment directed against the autoimmune process and treatment of the underlying malignancy.</p></div></div></div><div class=section><a name=d6625e703 class=n-a></a><h3 class=section-title>The role of tumor antigens in the pathogenesis of paraneoplastic neurological disease</h3><p class="" id=d6625e708>That tumors may harbor antigens cross-reactive with neuronal proteins was demonstrated by early investigators<sup><a href="#ref-1">1</a>–<a href="#ref-3">3</a></sup>, and subsequent work demonstrated that these antigens may be detected not only in patients with paraneoplastic neurological disease but also in cancer patients who remain neurologically normal<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. More recent studies of ovarian tumors from patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies, the major antibodies associated with the condition, have demonstrated that, although ovarian tumors from anti-Yo–positive and anti-Yo–negative patients were histologically similar, ovarian tumors from anti-Yo–positive patients differ from tumors from patients without anti-Yo antibodies by high rates of genetic alterations in key CDR and, to a greater extent, CDR2L (CDR2-like) Yo antigens and by intense tumor infiltration by plasma cells and cytotoxic CD8<sup>+</sup> lymphocytes<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. Recent studies of ovarian teratomas from patients with anti–<i>N</i>-methyl-D-aspartate receptor (anti-NMDAR) encephalitis have shown that teratomas from NMDAR encephalitis are much more likely to contain predominantly glial elements suggestive of neuroglial tumors than those without encephalitis and may also have extensive infiltrates of T and B cells as well as IgG and IgA deposits in close contact with the neuroglial components of the teratomas<sup><a href="#ref-14">14</a></sup>. All of these more recent data suggest that tumors from patients with paraneoplastic neurological syndromes may have unique properties capable of breaking immune tolerance and triggering a vigorous B- and T-cell response.</p></div><div class=section><a name=d6625e745 class=n-a></a><h3 class=section-title>Syndromes associated with antibodies to cell membrane antigens</h3><p class="" id=d6625e750>In this group of conditions, neuronal injury occurs when antibodies bind to and impair the function of neuronal membrane proteins. The best studied of these conditions is anti-NMDAR encephalitis. This condition was initially described in women with ovarian teratomas but may also occur in the absence of underlying neoplasia and can also affect males. In anti-NMDAR encephalitis, antibody binding to the NMDAR results in receptor cross-linking internalization and in depletion of receptors on the cell surface<sup><a href="#ref-15">15</a>–<a href="#ref-17">17</a></sup>. Similar immunological mechanisms are thought to be shared by conditions associated with antibodies to the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and many but not all other antibodies to cell surface antigens<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. An important point in these conditions is that reconstitution of neuronal surface receptors may occur slowly and may require protracted therapy over weeks to months<sup><a href="#ref-21">21</a></sup>.</p></div><div class=section><a name=d6625e772 class=n-a></a><h3 class=section-title>Syndromes associated with an immune response to intracellular neuronal proteins</h3><p class="" id=d6625e777>The mechanisms of neuronal injury in this group of conditions have remained controversial and understanding of the role of these antibodies in disease pathogenesis has been greatly hindered by the lack of an animal model. Early attempts to produce paraneoplastic disease in animals by passive transfer of antibodies or immunization with antigen or nucleic acids were uniformly unsuccessful<sup><a href="#ref-22">22</a>–<a href="#ref-25">25</a></sup>, leading many investigators to conclude that the associated antibodies were simply markers for underlying neoplasia. T lymphocyte response in patients with antibodies to internal cellular proteins (for example, Yo and Hu) has been repeatedly demonstrated: infiltrates of cytotoxic (CD8<sup>+</sup>) lymphocytes have been detected in brains of patients with encephalomyelitis and anti-Hu antibody<sup><a href="#ref-26">26</a></sup> and in cerebrospinal fluid (CSF) of a patient with anti-Yo–associated paraneoplastic cerebellar degeneration<sup><a href="#ref-27">27</a></sup>. Cross-reactive T-cell receptors have been reported in brain and tumor tissue from a patient with paraneoplastic encephalomyelitis<sup><a href="#ref-28">28</a></sup>. Interestingly, however, Sillevis Smitt <i>et al</i>. failed to detect cytotoxic T lymphocytes in serum or CSF of patients with anti-Hu antibodies and paraneoplastic neurological disease<sup><a href="#ref-29">29</a>–<a href="#ref-31">31</a></sup>. We are aware of only one attempt to cause neuronal death using T cells sensitized to paraneoplastic antigens in an animal model. That study, by Pellkofer <i>et al</i>., though producing a predominantly meningitis response, did not duplicate paraneoplastic neurological disease<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d6625e820>The role of antibodies in causing neuronal injury is controversial. Neurons have traditionally been considered to exclude immunoglobulins (IgG); for this reason, it has been thought unlikely that antibodies could reach their intracellular antigenic targets. However, the ability of neurons in living animals to incorporate immunoglobulins was demonstrated many years ago by Fabian and Petroff<sup><a href="#ref-33">33</a></sup> and was suggested by Griffin <i>et al</i>.<sup><a href="#ref-34">34</a></sup> in experimental Sindbis virus infection. Neuronal uptake of paraneoplastic and other IgGs was documented by Graus <i>et al</i>.<sup><a href="#ref-23">23</a></sup> in studies using intraventricular infusion of IgG in guinea pigs and by Greenlee <i>et al</i>.<sup><a href="#ref-35">35</a></sup> following blood–brain barrier disruption after intraperitoneal injection of anti-Yo IgG. Both our laboratory and that of Vedeler <i>et al</i>. have demonstrated that anti-Yo IgG can be taken up by Purkinje cells in rat cerebellar slice cultures and can cause cell death<sup><a href="#ref-36">36</a>–<a href="#ref-39">39</a></sup>; and anti-Hu IgG, associated with encephalomyelitis in the setting of small-cell lung cancer, has been shown to produce neuronal death in dispersed cultures of cerebellar neurons and of multiple neuronal populations in slice cultures of rat brains<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>. These studies have not been extended to living animals, however, and a major challenge in developing such a model has been the difficulty of achieving antibody penetration across the blood–brain barrier into brain over prolonged periods of time. Study of a third possible mechanism of injury—that paraneoplastic neuronal injury involves both T and B cells—must also await the development of an animal model.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6625e870>Clinical presentations of major paraneoplastic neurological syndromes</h2><div class=section><a name=d6625e873 class=n-a></a><h3 class=section-title>Anti-NMDAR encephalitis</h3><p class="" id=d6625e878>Anti-NMDAR encephalitis was initially described in women with ovarian teratomas but can occur in patients with other (predominantly germ cell) neoplasms and also in both females and males without neoplasia<sup><a href="#ref-4">4</a>,<a href="#ref-21">21</a></sup>. It can also occur as apparent clinical relapse in patients recovering from herpes simplex virus encephalitis<sup><a href="#ref-42">42</a></sup>. Anti-NMDAR encephalitis remains by far the most commonly diagnosed disorder associated with antineuronal autoantibodies and its frequency surpasses those of individual viral encephalitides<sup><a href="#ref-43">43</a></sup>. The disorder is complex, and a range of symptoms suggests the involvement of multiple brain regions and can include cognitive and memory deficits, refractory seizures (including status epilepticus), significant dysautonomia, limbic symptoms, psychiatric disturbances (including agitation paranoia), catatonia, movement disorders, seizures, autonomic dysfunction, hypoventilation which may require artificial ventilation, and coma<sup><a href="#ref-21">21</a>,<a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup>. Patients often present initially with behavioral changes, including insomnia, agitation, paranoia, and hallucinations, developing over several weeks to months<sup><a href="#ref-47">47</a></sup>. Magnetic resonance imaging (MRI) often demonstrates T2 hyperintensity within the mesial temporal lobes<sup><a href="#ref-48">48</a></sup>. An electroencephalogram (EEG) may demonstrate temporal slowing or epileptogenic activity<sup><a href="#ref-49">49</a></sup>. Very few cases of NMDAR encephalitis have come to autopsy but these suggest some degree of neuronal loss and extensive brain infiltration by lymphoid cells, in particular by B cells and plasma cells. The disorder is often responsive to immunomodulatory therapy, including steroids, plasma exchange, intravenous immunoglobulin (IVIG), and rituximab. Recovery, however, may require prolonged treatment over weeks to months, and some patients can relapse.</p></div><div class=section><a name=d6625e920 class=n-a></a><h3 class=section-title>Autoimmune encephalitis with antibodies to the voltage-gated potassium channel complex: LGI1 and CASPR2</h3><p class="" id=d6625e925>Autoimmune encephalitis associated with antibodies to LGI1 and CASPR2 is only infrequently associated with underlying malignancy; however, in patients positive for both antibodies, the likelihood of cancer approaches 44% and thymomas constitute the majority of these cases<sup><a href="#ref-50">50</a></sup>. Anti-LGI1 encephalitis is typically characterized by faciobrachial dystonic episodes that may or may not have an ictal EEG accompaniment. Anti-CASPR2 encephalitis was initially associated with Morvan’s syndrome. Both entities, however, may have much more complex central and peripheral semiology, including seizures, psychiatric or personality changes, autonomic instability, and peripheral neuropathic symptoms. Thirty-nine percent of patients with anti-LGI1 antibodies will exhibit hyponatremia. As with anti-NMDAR encephalitis, response to immunomodulatory treatment is often excellent, but treatment may need to be prolonged.</p></div><div class=section><a name=d6625e933 class=n-a></a><h3 class=section-title>Subacute (paraneoplastic) cerebellar degeneration</h3><p class="" id=d6625e938>Paraneoplastic cerebellar degeneration is characterized by remorselessly progressive signs of cerebellar injury, including central and appendicular ataxia, vertigo, and nystagmus. As the disease progresses, the severity of cerebellar deficits is often well beyond that of most other cerebellar syndromes, leaving the individual unable to sit, stand, or even speak<sup><a href="#ref-51">51</a></sup>. MRI brain in these patients may be initially normal but later may demonstrate cerebellar atrophy<sup><a href="#ref-52">52</a></sup>. Major associated tumors include gynecological and breast malignancies, small-cell lung cancer, and Hodgkin’s disease. Paraneoplastic cerebellar degeneration should be considered as a diagnosis in any adult patient with subacute progressive cerebellar ataxia in the absence of a family history.</p><p class="" id=d6625e949>Paraneoplastic cerebellar degeneration may be accompanied by any of several well-described antibodies, and the most common include anti-Yo (PCA-1), PCA-2, anti-Hu (ANNA-1) anti-Ri (ANNA-2), and anti-Tr<sup><a href="#ref-52">52</a></sup>. Rare cases may be associated with antibodies to the metabotropic glutamate receptors, mGluR1 and mGluR2<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup>. The antibody is often suggestive of the underlying tumor, with anti-Yo most often associated with breast or gynecological malignancies, anti-Ri associated with breast or lung malignancies, anti-PCA-2 with lung malignancies<sup><a href="#ref-55">55</a>–<a href="#ref-57">57</a></sup>, and anti-Tr and anti-mGluR1 with Hodgkin’s disease<sup><a href="#ref-53">53</a>,<a href="#ref-58">58</a>,<a href="#ref-59">59</a></sup>. Cerebellar symptoms in patients with anti-Ri and anti-Hu antibodies may be accompanied by opsoclonus. With the exception of cases associated with anti-mGluR1 and possibly those associated with anti-Ri, the course of disease is characterized by progressive, irreversible neuronal loss, making early treatment of great importance and limiting response to immunotherapy as the disease progresses<sup><a href="#ref-60">60</a></sup>.</p></div><div class=section><a name=d6625e985 class=n-a></a><h3 class=section-title>Paraneoplastic encephalomyelitis</h3><p class="" id=d6625e990>Encephalomyelitis refers to inflammation of the brain or spinal cord (or both) and may present with cortical, brain stem, or spinal involvement either in isolation or concomitantly. Discussed below are specific presentations that clinicians should be aware of while remaining cognizant that one or more may be present at the same time. Anti-NMDAR encephalitis is discussed above.</p><p class="" id=d6625e993><b><i>Limbic encephalitis.</i></b> Encephalitis involving primarily the limbic system is characterized by a constellation of symptoms and signs that may include personality changes, irritability, depression, seizures, memory loss, and sometimes dementia<sup><a href="#ref-47">47</a>,<a href="#ref-61">61</a></sup>. Limbic encephalitis has been associated with many different antineuronal antibodies. Anti-Hu and anti-Ma2 antibodies have well-described associations with small-cell lung cancer and testicular germ cell tumors, respectively<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. Anti-mGluR5 antibodies may be associated with limbic encephalitis in Hodgkin’s disease<sup><a href="#ref-58">58</a></sup>. Anti-GABAbR and anti-AMPAR antibodies are most commonly associated with small-cell lung cancer and breast cancer or thymoma, respectively<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. Other antibodies that may be associated with limbic encephalitis include those to amphiphysin, Caspr2, LGI1, and GAD65: these may have associated malignancies but, except in cases where antibodies to Caspr2 and LGI1 are present together, more frequently occur in the absence of malignant disease<sup><a href="#ref-66">66</a>–<a href="#ref-71">71</a></sup>.</p><p class="" id=d6625e1031><b><i>Brain-stem encephalitis.</i></b> Brain-stem involvement in paraneoplastic disease may present with varying phenotypes, depending on the region of the brain stem that is involved. Gaze palsies present in midbrain involvement, facial palsy or vertical gaze palsies present in pontine involvement, dysarthria or dysphagia or central hypoventilation present in medullary involvement have been documented; patients may also have pyramidal symptoms and gait impairment<sup><a href="#ref-62">62</a>,<a href="#ref-72">72</a></sup>. Anti-Hu and Ma2, associated most commonly with small-cell lung cancer and testicular tumors, respectively, should be strongly considered. Immunotherapy may stabilize symptoms to some degree; however, improvement is often limited, emphasizing the importance of early diagnosis and treatment<sup><a href="#ref-62">62</a>,<a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. One peculiar syndrome is opsoclonus myoclonus syndrome, which is characterized by rapid and jerking eye movements that are accompanied by myoclonic movements of the extremities and ataxia<sup><a href="#ref-74">74</a></sup>. Serologically, anti-Hu and anti-Ri antibodies are most commonly associated with this syndrome in adults<sup><a href="#ref-75">75</a>,<a href="#ref-76">76</a></sup>. In children, neuroblastoma is the most frequently associated malignancy<sup><a href="#ref-77">77</a></sup>. Recently, Kelch-like protein 11 antibodies were identified in patients with brain-stem and cerebellar symptoms and associated testicular seminomas<sup><a href="#ref-78">78</a></sup>.</p><p class="" id=d6625e1074><b><i>Myelitis.</i></b> Paraneoplastic myelitis should be considered in patients presenting with subacute myelopathy. Presenting symptoms may be non-specific and consistent with myelitis, including flaccid or spastic paraparesis or tetraparesis, urinary or bowel dysfunction, or sensory loss. Rarely, cancer may be accompanied by involvement of spinal cord motor neurons to produce a syndrome suggestive of amyotrophic lateral sclerosis<sup><a href="#ref-79">79</a></sup>. Paraneoplastic myelitis most commonly occurs in patients with underlying small-cell lung or breast neoplasms. CSF analysis may demonstrate pleocytosis, elevated protein, or the presence of oligoclonal bands with imaging classically demonstrating longitudinally tract-specific enhancement but can be normal in some patients<sup><a href="#ref-80">80</a></sup>. Paraneoplastic myelitis is most frequently associated with anti-Hu antibodies, and fewer cases are associated with anti-Ri or anti-CRMP5<sup><a href="#ref-79">79</a>,<a href="#ref-81">81</a>–<a href="#ref-83">83</a></sup>. Necrotizing myelitis has also been described; it has a more fulminant presentation, which can occur without associated paraneoplastic antibodies<sup><a href="#ref-84">84</a></sup>.</p></div><div class=section><a name=d6625e1104 class=n-a></a><h3 class=section-title>Dorsal sensory neuropathy</h3><p class="" id=d6625e1109>Dorsal root ganglionopathies typically present with subacute, asymmetrical, often painful progressive sensory loss usually affecting proprioception and vibratory sensation in comparison with temperature and discriminatory touch<sup><a href="#ref-85">85</a></sup>. There may also be an association with additional autonomic, cerebral, or cerebellar symptoms<sup><a href="#ref-86">86</a></sup>. CSF analysis often demonstrates pleocytosis or the presence of oligoclonal bands, and nerve conduction studies are particularly helpful in localizing involvement in the dorsal root ganglia rather than peripheral nerves<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>. Dorsal sensory neuronopathy may occur in the setting of small-cell lung cancer, and patients will often have anti-Hu antibodies<sup><a href="#ref-89">89</a>,<a href="#ref-90">90</a></sup>. Dorsal sensory neuronopathy may also occur in non-cancerous disorders such as Sjögren syndrome<sup><a href="#ref-89">89</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6625e1142>Evaluation and diagnosis</h2><p class="" id=d6625e1145>The clinical presentation of paraneoplastic neurological disease varies widely and often requires a high degree of clinical suspicion in order not to miss the diagnosis. Although the onset of symptoms can be very rapid, most patients develop symptoms in a subacute manner over weeks or sometimes months. Patients may have coexisting autoimmune disease, a family history of autoimmunity or cancer, or risk factors for malignancy. CSF evaluation is essential in these patients. In many patients, CSF analysis may demonstrate pleocytosis, elevated protein, or the presence of oligoclonal bands or a combination of these. In some patients, however, normal CSF does not exclude the possibility of paraneoplastic neurological injury<sup><a href="#ref-91">91</a></sup>. As the clinical presentation of a specific antibody can vary widely, our recommendation is to test with antibody panels, which are commercially available, rather than single-antibody testing<sup><a href="#ref-92">92</a></sup>. There is frequently a time lag before results of antibody testing become available. For this reason, prompt empiric therapy should be considered, especially in patients with rapidly worsening syndromes.</p><p class="" id=d6625e1156>In patients with suspected paraneoplastic neurological disease, screening for underlying malignancy is mandatory. Positron emission tomography (PET) is more sensitive to smaller tumors than computed tomography. Antineuronal antibodies may act as markers for specific tumors such as breast or reproductive organ tumors for anti-Yo, small-cell lung cancer for anti-Hu, breast or lung for anti-Ri, or testicle for anti-Ma2. Additional testing, including mammography and pelvic or testicular ultrasound, may be necessary. If malignancy is identified with imaging, treatment should be guided with the aid on an oncologist. Guidelines for diagnosis and tumor search are available<sup><a href="#ref-93">93</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d6625e1166>Treatment</h2><p class="" id=d6625e1169>Prompt initiation of treatment in paraneoplastic disease—especially where the condition is accompanied by antibodies to intracellular antigens—is essential to prevent substantial permanent neurological impairment or death. As testing may take several days to return, we recommend empiric treatment while awaiting results in patients who are highly suspicious for paraneoplastic disease. Subacute onset, focal neurological deficits, abnormal T2 hyperintensity in the temporal lobes on MRI, and inflammatory CSF are suggestive of an underlying antibody-mediated etiology and should prompt the provider to consider immunotherapy<sup><a href="#ref-94">94</a></sup>. Although there are no controlled trials to date to guide therapy decisions in paraneoplastic disease, many therapeutic approaches have been employed. Treatment is thus empiric and should be based on the severity of the underlying pathological antibody, the patient’s condition, co-morbid medical conditions, and response to immunotherapy.</p><p class="" id=d6625e1176>Treatment of paraneoplastic neurological syndromes begins with therapies addressing the underlying malignancy if one is known or attempts to identify and treat a malignancy not yet detected. Response to treatment of the neurological disorder differs between syndromes associated with antibodies to cell membrane antigens, such as anti-NMDAR encephalitis, and syndromes associated with antibodies reactive with intracellular antigens, such as anti-Yo or anti-Hu. Paraneoplastic neurological syndromes associated with antibodies to cell membrane antigens, such as anti-NMDAR, frequently exhibit a good response to treatment. Intravenous methylprednisolone, usually given as 1000 mg daily for 3 to 5 days, is often used as first-line therapy<sup><a href="#ref-95">95</a></sup>. Methylprednisolone is often combined or with or followed by treatment with plasma exchange or IVIG or both. Plasma exchange may be carried out using exchanges on an every-other-day basis for a total of five to seven sessions<sup><a href="#ref-96">96</a></sup>. IVIG is typically dosed at 2 g/kg over three to five days<sup><a href="#ref-97">97</a></sup>. Clinicians should be aware that performing plasmapheresis following IVIG administration will remove the therapeutic IgG just administered. For this reason, plasma exchange should always be performed prior to IVIG. Patients failing these modalities should be considered for treatment with rituximab, typically administered as 1000 mg intravenously for two doses 14 days apart followed by every-six-months dosing, or cyclophosphamide, typically dosed 500 to 1000 mg/m<sup>2</sup> every month<sup><a href="#ref-98">98</a>,<a href="#ref-99">99</a></sup>. Also crucial to the long-term treatment in these patients are the identification and treatment of their underlying malignancy<sup><a href="#ref-100">100</a></sup>.</p><p class="" id=d6625e1206>Treatment of paraneoplastic neurological disease involving antibodies against intracellular antigens such as anti-Hu, anti-Yo, and anti-Ri tends to be more difficult. Corticosteroids, plasma exchange, IVIG, rituximab, and cyclophosphamide have all been used with varying—and usually poor—degrees of success<sup><a href="#ref-13">13</a></sup>. In these conditions, irreversible neuronal loss occurs over time, making prompt or even urgent treatment extremely important. Evidence suggests that patients may have a better prognosis with earlier initiation of treatment, and pathological studies clearly demonstrate that neuronal loss occurs over time<sup><a href="#ref-101">101</a>,<a href="#ref-102">102</a></sup>. Although treatment may induce only partial remission of neurological symptoms, prompt initiation of therapy may still allow significant functional improvement<sup><a href="#ref-13">13</a>,<a href="#ref-103">103</a>,<a href="#ref-104">104</a></sup>. Similar to syndromes associated with antibodies against neuronal membranes, intravenous methylprednisolone is often used as initial treatment, with consideration of concomitant treatment with IVIG in more severe cases Plasmapheresis is a reasonable strategy to consider, although the paraneoplastic antibody may not be removed from the CNS and patients often do not respond to treatment<sup><a href="#ref-13">13</a></sup>. Both cyclophosphamide and rituximab have been used with some benefit in paraneoplastic disorders, although neither treatment has demonstrated consistent response or decreasing titers of antibody<sup><a href="#ref-13">13</a>,<a href="#ref-60">60</a>,<a href="#ref-105">105</a>,<a href="#ref-106">106</a></sup>. One difficulty in determining the effect of different treatment modalities in these conditions is that, in most reports, therapy has been instituted late in the disease course, at a time when neuronal injury and death are already extensive. Importantly, treatment of the underlying tumor is imperative to preventing additional progression of the neurological syndrome associated with the paraneoplastic antibody<sup><a href="#ref-13">13</a>,<a href="#ref-106">106</a></sup>.</p><p class="" id=d6625e1255>Treatment of any paraneoplastic neurological disorder should be closely coordinated with an experienced care team, including an oncologist, neurologist, and surgeon if necessary. Treatment decisions regarding immunotherapy should be agreed upon within the care team, taking into account the timing of necessary radiation or chemotherapy and its effect on timing of immunotherapy. Prompt treatment of the underlying malignancy is important in the overall patient outcome.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d6625e1262 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d7279>References</h2><div class="section ref-list"><a name=d6625e1262 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d6625e1269 class=n-a></a>Furneaux HM, Rosenblum MK, Dalmau J, <i> et al.</i>: Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. <i>N Engl J Med.</i> 1990; <b>322</b>(26): 1844–51. <a target=xrefwindow id=d6625e1280 href="http://www.ncbi.nlm.nih.gov/pubmed/2348838">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1283 href="https://doi.org/10.1056/NEJM199006283222604">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d6625e1292 class=n-a></a>Dropcho EJ, Furneaux H, Chen YT, <i> et al.</i>: Expression of the CDR brain protein by tumors from patients with paraneoplastic cerebellar degeneration. <i>Ann Neurol.</i> 1988; <b>24</b>: 121–2. </span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d6625e1310 class=n-a></a>Manley GT, Smitt PS, Dalmau J, <i> et al.</i>: Hu antigens: Reactivity with hu antibodies, tumor expression, and major immunogenic sites. <i>Ann Neurol.</i> 1995; <b>38</b>(1): 102–10. <a target=xrefwindow id=d6625e1321 href="http://www.ncbi.nlm.nih.gov/pubmed/7541976">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1324 href="https://doi.org/10.1002/ana.410380117">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1074742"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1333 class=n-a></a>Dalmau J, Tüzün E, Wu HY, <i> et al.</i>: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. <i>Ann Neurol.</i> 2007; <b>61</b>(1): 25–36. <a target=xrefwindow id=d6625e1344 href="http://www.ncbi.nlm.nih.gov/pubmed/17262855">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1347 href="https://doi.org/10.1002/ana.21050">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2430743">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1074742">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d6625e1364 class=n-a></a>Wilkinson PC, Zeromski J: Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. <i>Brain.</i> 1965; <b>88</b>(3): 529–83. <a target=xrefwindow id=d6625e1372 href="http://www.ncbi.nlm.nih.gov/pubmed/5318822">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1375 href="https://doi.org/10.1093/brain/88.3.529">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d6625e1385 class=n-a></a>Trotter JL, Hendin BA, Osterland CK: Cerebellar degeneration with Hodgkin disease. An immunological study. <i>Arch Neurol.</i> 1976; <b>33</b>(9): 660–1. <a target=xrefwindow id=d6625e1393 href="http://www.ncbi.nlm.nih.gov/pubmed/962649">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1396 href="https://doi.org/10.1001/archneur.1976.00500090066014">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d6625e1405 class=n-a></a>Greenlee JE, Brashear HR: Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. <i>Ann Neurol.</i> 1983; <b>14</b>(6): 609–13. <a target=xrefwindow id=d6625e1413 href="http://www.ncbi.nlm.nih.gov/pubmed/ 6360029 ">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1416 href="https://doi.org/10.1002/ana.410140603">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d6625e1425 class=n-a></a>Jaeckle KA, Graus F, Houghton A, <i> et al.</i>: Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. <i>Ann Neurol.</i> 1985; <b>18</b>(5): 592–600. <a target=xrefwindow id=d6625e1436 href="http://www.ncbi.nlm.nih.gov/pubmed/2416270">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1439 href="https://doi.org/10.1002/ana.410180513">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737433067"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1448 class=n-a></a>Raspotnig M, Haugen M, Thorsteinsdottir M, <i> et al.</i>: Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies. <i>Cancer Immunol Immunother.</i> 2017; <b>66</b>(11): 1463–71. <a target=xrefwindow id=d6625e1459 href="http://www.ncbi.nlm.nih.gov/pubmed/28710511">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1462 href="https://doi.org/10.1007/s00262-017-2041-8">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737433067">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d6625e1475 class=n-a></a>Darnell JC, Albert ML, Darnell RB: Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. <i>Cancer Res.</i> 2000; <b>60</b>(8): 2136–9. <a target=xrefwindow id=d6625e1483 href="http://www.ncbi.nlm.nih.gov/pubmed/10786675">PubMed Abstract </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732398099"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1492 class=n-a></a>Small M, Treilleux I, Couillault C, <i> et al.</i>: Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. <i>Acta Neuropathol.</i> 2018; <b>135</b>(4): 569–79. <a target=xrefwindow id=d6625e1503 href="http://www.ncbi.nlm.nih.gov/pubmed/29299667">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1506 href="https://doi.org/10.1007/s00401-017-1802-y">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732398099">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733450397"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1520 class=n-a></a>Vialatte de Pémille C, Berzero G, Small M, <i> et al.</i>: Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies. <i>Br J Cancer.</i> 2018; <b>119</b>(1): 105–13. <a target=xrefwindow id=d6625e1531 href="http://www.ncbi.nlm.nih.gov/pubmed/29899393">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1534 href="https://doi.org/10.1038/s41416-018-0125-7">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1538 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6035206">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733450397">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d6625e1551 class=n-a></a>Greenlee JE: Treatment of paraneoplastic neurologic disorders. <i>Curr Treat Options Neurol.</i> 2010; <b>12</b>(3): 212–30. <a target=xrefwindow id=d6625e1559 href="http://www.ncbi.nlm.nih.gov/pubmed/20842583">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1562 href="https://doi.org/10.1007/s11940-010-0066-9">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735312487"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1571 class=n-a></a>Chefdeville A, Treilleux I, Mayeur ME, <i> et al.</i>: Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis. <i>Acta Neuropathol Commun.</i> 2019; <b>7</b>(1): 38. <a target=xrefwindow id=d6625e1582 href="http://www.ncbi.nlm.nih.gov/pubmed/30857565">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1585 href="https://doi.org/10.1186/s40478-019-0693-7">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1589 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6410529">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735312487">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d6625e1602 class=n-a></a>Manto M, Dalmau J, Didelot A, <i> et al.</i>: In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: Further evidence of synaptic glutamatergic dysfunction. <i>Orphanet J Rare Dis.</i> 2010; <b>5</b>: 31. <a target=xrefwindow id=d6625e1613 href="http://www.ncbi.nlm.nih.gov/pubmed/21110857">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1616 href="https://doi.org/10.1186/1750-1172-5-31">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1620 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3002330">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725235037"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1629 class=n-a></a>Planagumà J, Leypoldt F, Mannara F, <i> et al.</i>: Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. <i>Brain.</i> 2015; <b>138</b>(Pt 1): 94–109. <a target=xrefwindow id=d6625e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/25392198">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1643 href="https://doi.org/10.1093/brain/awu310">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1647 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4285189">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725235037">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/3571956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1660 class=n-a></a>Hughes EG, Peng X, Gleichman AJ, <i> et al.</i>: Cellular and Synaptic Mechanisms of Anti-NMDA Receptor Encephalitis. <i>J Neurosci.</i> 2010; <b>30</b>(17): 5866–75. <a target=xrefwindow id=d6625e1671 href="http://www.ncbi.nlm.nih.gov/pubmed/20427647">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1674 href="https://doi.org/10.1523/JNEUROSCI.0167-10.2010">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1678 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2868315">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/3571956">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d6625e1692 class=n-a></a>Lai M, Hughes EG, Peng X, <i> et al.</i>: AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. <i>Ann Neurol.</i> 2009; <b>65</b>(4): 424–34. <a target=xrefwindow id=d6625e1703 href="http://www.ncbi.nlm.nih.gov/pubmed/19338055">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1706 href="https://doi.org/10.1002/ana.21589">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1710 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2677127">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733155203"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e1719 class=n-a></a>Nibber A, Mann EO, Pettingill P, <i> et al.</i>: Pathogenic potential of antibodies to the GABAB receptor. <i>Epilepsia Open.</i> 2017; <b>2</b>(3): 355–9. <a target=xrefwindow id=d6625e1730 href="http://www.ncbi.nlm.nih.gov/pubmed/29588966">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1733 href="https://doi.org/10.1002/epi4.12067">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1737 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5862107">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733155203">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d6625e1750 class=n-a></a>Peng X, Hughes EG, Moscato EH, <i> et al.</i>: Cellular plasticity induced by anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. <i>Ann Neurol.</i> 2015; <b>77</b>(3): 381–98. <a target=xrefwindow id=d6625e1761 href="http://www.ncbi.nlm.nih.gov/pubmed/25369168">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1764 href="https://doi.org/10.1002/ana.24293">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1768 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4365686">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d6625e1777 class=n-a></a>Dalmau J: NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture. <i>Neurology.</i> 2016; <b>87</b>(23): 2471–82. <a target=xrefwindow id=d6625e1785 href="http://www.ncbi.nlm.nih.gov/pubmed/27920282">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1788 href="https://doi.org/10.1212/WNL.0000000000003414">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1791 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5177671">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d6625e1800 class=n-a></a>Tanaka K, Tanaka M, Igarashi S, <i> et al.</i>: Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. <i>Clin Neurol Neurosurg.</i> 1995; <b>97</b>(1): 101–5. <a target=xrefwindow id=d6625e1811 href="http://www.ncbi.nlm.nih.gov/pubmed/7788964">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1814 href="https://doi.org/10.1016/0303-8467(95)00006-6">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d6625e1823 class=n-a></a>Graus F, Illa I, Agusti M, <i> et al.</i>: Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. <i>J Neurol Sci.</i> 1991; <b>106</b>(1): 82–7. <a target=xrefwindow id=d6625e1834 href="http://www.ncbi.nlm.nih.gov/pubmed/1779243">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1837 href="https://doi.org/10.1016/0022-510x(91)90198-g">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d6625e1847 class=n-a></a>Sillevis Smitt PA, Manley GT, Posner JB: Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. <i>Neurology.</i> 1995; <b>45</b>(10): 1873–8. <a target=xrefwindow id=d6625e1855 href="http://www.ncbi.nlm.nih.gov/pubmed/7477985">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1858 href="https://doi.org/10.1212/wnl.45.10.1873">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d6625e1867 class=n-a></a>Sakai K, Gofuku M, Kitagawa Y, <i> et al.</i>: Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. <i>J Neuroimmunol.</i> 1995; <b>60</b>(1–2): 135–41. <a target=xrefwindow id=d6625e1878 href="http://www.ncbi.nlm.nih.gov/pubmed/7642741">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1881 href="https://doi.org/10.1016/0165-5728(95)00063-8">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d6625e1890 class=n-a></a>Voltz R, Dalmau J, Posner JB, <i> et al.</i>: T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. <i>Neurology.</i> 1998; <b>51</b>(4): 1146–50. <a target=xrefwindow id=d6625e1901 href="http://www.ncbi.nlm.nih.gov/pubmed/9781545">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1904 href="https://doi.org/10.1212/wnl.51.4.1146">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d6625e1913 class=n-a></a>Albert ML, Austin LM, Darnell RB: Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. <i>Ann Neurol.</i> 2000; <b>47</b>(1): 9–17. <a target=xrefwindow id=d6625e1921 href="http://www.ncbi.nlm.nih.gov/pubmed/10632096">PubMed Abstract </a> | <a target="xrefwindow" id="d6625e1924" href="https://doi.org/10.1002/1531-8249(200001)47:1<9::AID-ANA5&gt;3.0.CO;2-I">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d6625e1933 class=n-a></a>Pellkofer HL, Voltz R, Goebels N, <i> et al.</i>: Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. <i>Arch Neurol.</i> 2009; <b>66</b>(5): 655–8. <a target=xrefwindow id=d6625e1944 href="http://www.ncbi.nlm.nih.gov/pubmed/19433667">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1947 href="https://doi.org/10.1001/archneurol.2009.56">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d6625e1956 class=n-a></a>de Jongste AHC, de Graaf MT, Martinuzzi E, <i> et al.</i>: Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies. <i>Neuro Oncol.</i> 2012; <b>14</b>(7): 841–8. <a target=xrefwindow id=d6625e1967 href="http://www.ncbi.nlm.nih.gov/pubmed/22591661">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1970 href="https://doi.org/10.1093/neuonc/nos118">Publisher Full Text </a> | <a target=xrefwindow id=d6625e1974 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3379804">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d6625e1984 class=n-a></a>de Beukelaar JW, Milikan JC, Verjans GM, <i> et al.</i>: No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes. <i>J Neurol.</i> 2009; <b>256</b>(2): 279–82. <a target=xrefwindow id=d6625e1995 href="http://www.ncbi.nlm.nih.gov/pubmed/19252764">PubMed Abstract </a> | <a target=xrefwindow id=d6625e1998 href="https://doi.org/10.1007/s00415-009-0051-y">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d6625e2007 class=n-a></a>de Beukelaar JW, Verjans GM, van Norden Y, <i> et al.</i>: No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. <i>Cancer Immunol Immunother.</i> 2007; <b>56</b>(9): 1501–6. <a target=xrefwindow id=d6625e2018 href="http://www.ncbi.nlm.nih.gov/pubmed/17597332">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2021 href="https://doi.org/10.1007/s00262-007-0295-2">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1914259">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1020517"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2034 class=n-a></a>Pellkofer H, Schubart AS, Höftberger R, <i> et al.</i>: Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. <i>Brain.</i> 2004; <b>127</b>(Pt 8): 1822–30. <a target=xrefwindow id=d6625e2045 href="http://www.ncbi.nlm.nih.gov/pubmed/15201193">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2048 href="https://doi.org/10.1093/brain/awh205">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1020517">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d6625e2061 class=n-a></a>Fabian RH, Petroff G: Intraneuronal IgG in the central nervous system: Uptake by retrograde axonal transport. <i>Neurology.</i> 1987; <b>37</b>(11): 1780. <a target=xrefwindow id=d6625e2069 href="http://www.ncbi.nlm.nih.gov/pubmed/2444904">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2072 href="https://doi.org/10.1212/wnl.37.11.1780">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d6625e2081 class=n-a></a>Griffin D, Levine B, Tyor W, <i> et al.</i>: The role of antibody in recovery from alphavirus encephalitis. <i>Immunol Rev.</i> 1997; <b>159</b>: 155–61. <a target=xrefwindow id=d6625e2092 href="http://www.ncbi.nlm.nih.gov/pubmed/9416509">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2095 href="https://doi.org/10.1111/j.1600-065x.1997.tb01013.x">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d6625e2104 class=n-a></a>Greenlee JE, Burns JB, Rose JW, <i> et al.</i>: Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption. <i>Acta Neuropathol.</i> 1995; <b>89</b>(4): 341–5. <a target=xrefwindow id=d6625e2115 href="http://www.ncbi.nlm.nih.gov/pubmed/7610765">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2118 href="https://doi.org/10.1007/bf00309627">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d6625e2128 class=n-a></a>Greenlee JE, Clawson SA, Hill KE, <i> et al.</i>: Anti-Yo Antibody Uptake and Interaction with Its Intracellular Target Antigen Causes Purkinje Cell Death in Rat Cerebellar Slice Cultures: A Possible Mechanism for Paraneoplastic Cerebellar Degeneration in Humans with Gynecological or Breast Cancers. <i>PLoS One.</i> 2015; <b>10</b>(4): e0123446. <a target=xrefwindow id=d6625e2139 href="http://www.ncbi.nlm.nih.gov/pubmed/25885452">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2142 href="https://doi.org/10.1371/journal.pone.0123446">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2146 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4401511">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d6625e2155 class=n-a></a>Greenlee JE, Clawson SA, Hill KE, <i> et al.</i>: Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. <i>J Neuropathol Exp Neurol.</i> 2010; <b>69</b>(10): 997–1007. <a target=xrefwindow id=d6625e2166 href="http://www.ncbi.nlm.nih.gov/pubmed/20838245">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2169 href="https://doi.org/10.1097/NEN.0b013e3181f0c82b">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2173 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2959164">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d6625e2182 class=n-a></a>Panja D, Vedeler CA, Schubert M: Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity. <i>Neuropathol Appl Neurobiol.</i> 2019; <b>45</b>(2): 141–156. <a target=xrefwindow id=d6625e2190 href="http://www.ncbi.nlm.nih.gov/pubmed/29679372">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2193 href="https://doi.org/10.1111/nan.12492">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d6625e2202 class=n-a></a>Schubert M, Panja D, Haugen M, <i> et al.</i>: Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. <i>Acta Neuropathol.</i> 2014; <b>128</b>(6): 835–52. <a target=xrefwindow id=d6625e2213 href="http://www.ncbi.nlm.nih.gov/pubmed/25341622">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2216 href="https://doi.org/10.1007/s00401-014-1351-6">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4231287">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d6625e2229 class=n-a></a>Greenlee JE, Parks TN, Jaeckle KA: Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. <i>Neurology.</i> 1993; <b>43</b>(10): 2049. <a target=xrefwindow id=d6625e2237 href="http://www.ncbi.nlm.nih.gov/pubmed/8413965">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2240 href="https://doi.org/10.1212/wnl.43.10.2049">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d6625e2249 class=n-a></a>Greenlee JE, Clawson SA, Hill KE, <i> et al.</i>: Neuronal uptake of anti-Hu antibody, but not anti-Ri antibody, leads to cell death in brain slice cultures. <i>J Neuroinflammation.</i> 2014; <b>11</b>: 160. <a target=xrefwindow id=d6625e2260 href="http://www.ncbi.nlm.nih.gov/pubmed/25228406">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2263 href="https://doi.org/10.1186/s12974-014-0160-0">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2267 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4174281">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733703328"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2277 class=n-a></a>Armangue T, Spatola M, Vlagea A, <i> et al.</i>: Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurol.</i> 2018; <b>17</b>(9): 760–72. <a target=xrefwindow id=d6625e2288 href="http://www.ncbi.nlm.nih.gov/pubmed/30049614">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2291 href="https://doi.org/10.1016/S1474-4422(18)30244-8">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2295 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6128696">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733703328">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14263003"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2308 class=n-a></a>Gable MS, Sheriff H, Dalmau J, <i> et al.</i>: The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. <i>Clin Infect Dis.</i> 2012; <b>54</b>(7): 899–904. <a target=xrefwindow id=d6625e2319 href="http://www.ncbi.nlm.nih.gov/pubmed/22281844">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2322 href="https://doi.org/10.1093/cid/cir1038">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2326 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3297648">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14263003">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8406956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2339 class=n-a></a>Dalmau J, Lancaster E, Martinez-Hernandez E, <i> et al.</i>: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. <i>Lancet Neurol.</i> 2011; <b>10</b>(1): 63–74. <a target=xrefwindow id=d6625e2350 href="http://www.ncbi.nlm.nih.gov/pubmed/21163445">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2353 href="https://doi.org/10.1016/S1474-4422(10)70253-2">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2357 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3158385">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8406956">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d6625e2370 class=n-a></a>Johnson N, Henry C, Fessler AJ, <i> et al.</i>: Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. <i>Neurology.</i> 2010; <b>75</b>(16): 1480–2. <a target=xrefwindow id=d6625e2381 href="http://www.ncbi.nlm.nih.gov/pubmed/20826712">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2384 href="https://doi.org/10.1212/WNL.0b013e3181f8831a">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3039209">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d6625e2397 class=n-a></a>Titulaer MJ, Dalmau J: Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. <i>Neurology.</i> 2014; <b>82</b>(7): 550–1. <a target=xrefwindow id=d6625e2405 href="http://www.ncbi.nlm.nih.gov/pubmed/24443450">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2408 href="https://doi.org/10.1212/WNL.0000000000000131">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d6625e2417 class=n-a></a>Tüzün E, Dalmau J: Limbic encephalitis and variants: classification, diagnosis and treatment. <i>Neurologist.</i> 2007; <b>13</b>(5): 261–71. <a target=xrefwindow id=d6625e2425 href="http://www.ncbi.nlm.nih.gov/pubmed/17848866">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2428 href="https://doi.org/10.1097/NRL.0b013e31813e34a5">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d6625e2438 class=n-a></a>da Rocha AJ, Nunes RH, Maia AC Jr, <i> et al.</i>: Recognizing Autoimmune-Mediated Encephalitis in the Differential Diagnosis of Limbic Disorders. <i>AJNR Am J Neuroradiol.</i> 2015; <b>36</b>(12): 2196–205. <a target=xrefwindow id=d6625e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/26381566">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2452 href="https://doi.org/10.3174/ajnr.A4408">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d6625e2461 class=n-a></a>Pessa ME, Janes F, Gigli GL: Electroencephalographic Evaluation for Early Diagnosis of Limbic Encephalitis. <i>Clin EEG Neurosci.</i> 2016; <b>47</b>(3): 207–10. <a target=xrefwindow id=d6625e2469 href="http://www.ncbi.nlm.nih.gov/pubmed/25253433">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2472 href="https://doi.org/10.1177/1550059414547758">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727730680"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2481 class=n-a></a>Gadoth A, Pittock SJ, Dubey D, <i> et al.</i>: Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. <i>Ann Neurol.</i> 2017; <b>82</b>(1): 79–92. <a target=xrefwindow id=d6625e2492 href="http://www.ncbi.nlm.nih.gov/pubmed/28628235">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2495 href="https://doi.org/10.1002/ana.24979">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727730680">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d6625e2508 class=n-a></a>Brain L, Wilkinson M: Subacute cerebellar degeneration associated with neoplasms. <i>Brain.</i> 1965; <b>88</b>(3): 465–78. <a target=xrefwindow id=d6625e2516 href="http://www.ncbi.nlm.nih.gov/pubmed/5890520">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2519 href="https://doi.org/10.1093/brain/88.3.465">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d6625e2528 class=n-a></a>Vernino S: Paraneoplastic cerebellar degeneration. <i>Handb Clin Neurol.</i> 2012; <b>103</b>: 215–23. <a target=xrefwindow id=d6625e2536 href="https://doi.org/10.1016/B978-0-444-51892-7.00013-9">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d6625e2545 class=n-a></a>Sillevis Smitt P, Kinoshita A, de Leeuw B, <i> et al.</i>: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. <i>N Engl J Med.</i> 2000; <b>342</b>(1): 21–7. <a target=xrefwindow id=d6625e2556 href="http://www.ncbi.nlm.nih.gov/pubmed/10620645">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2559 href="https://doi.org/10.1056/NEJM200001063420104">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737076754"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2569 class=n-a></a>Ruiz-García R, Martínez-Hernández E, Joubert B, <i> et al.</i>: Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurol Neuroimmunol Neuroinflamm.</i> 2019; <b>7</b>(2): pii: e658. <a target=xrefwindow id=d6625e2580 href="http://www.ncbi.nlm.nih.gov/pubmed/31826987">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2583 href="https://doi.org/10.1212/NXI.0000000000000658">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2587 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6943365">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737076754">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d6625e2600 class=n-a></a>Venkatraman A, Opal P: Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. <i>Ann Clin Transl Neurol.</i> 2016; <b>3</b>(8): 655–63. <a target=xrefwindow id=d6625e2608 href="http://www.ncbi.nlm.nih.gov/pubmed/27606347">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2611 href="https://doi.org/10.1002/acn3.328">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4999597">Free Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d6625e2623 class=n-a></a>Pittock SJ, Lucchinetti CF, Lennon VA: Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. <i>Ann Neurol.</i> 2003; <b>53</b>(5): 580–7. <a target=xrefwindow id=d6625e2631 href="http://www.ncbi.nlm.nih.gov/pubmed/12730991">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2634 href="https://doi.org/10.1002/ana.10518">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d6625e2643 class=n-a></a>Vernino S, Lennon VA: New Purkinje cell antibody (PCA-2): Marker of lung cancer-related neurological autoimmunity. <i>Ann Neurol.</i> 2000; <b>47</b>(3): 297–305. <a target=xrefwindow id=d6625e2651 href="http://www.ncbi.nlm.nih.gov/pubmed/10716248">PubMed Abstract </a> | <a target="xrefwindow" id="d6625e2654" href="https://doi.org/10.1002/1531-8249(200003)47:3<297::AID-ANA4&gt;3.0.CO;2-4">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d6625e2663 class=n-a></a>Lancaster E, Martinez-Hernandez E, Titulaer MJ, <i> et al.</i>: Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. <i>Neurology.</i> 2011; <b>77</b>(18): 1698–701. <a target=xrefwindow id=d6625e2674 href="http://www.ncbi.nlm.nih.gov/pubmed/22013185">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2677 href="https://doi.org/10.1212/WNL.0b013e3182364a44">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2681 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3208954">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d6625e2690 class=n-a></a>Bernal F, Shams'ili S, Rojas I, <i> et al.</i>: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. <i>Neurology.</i> 2003; <b>60</b>(2): 230–4. <a target=xrefwindow id=d6625e2701 href="http://www.ncbi.nlm.nih.gov/pubmed/12552036">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2704 href="https://doi.org/10.1212/01.wnl.0000041495.87539.98">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d6625e2714 class=n-a></a>Keime-Guibert F, Graus F, Fleury A, <i> et al.</i>: Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. <i>J Neurol Neurosurg Psychiatry.</i> 2000; <b>68</b>(4): 479–82. <a target=xrefwindow id=d6625e2725 href="http://www.ncbi.nlm.nih.gov/pubmed/10727484">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2728 href="https://doi.org/10.1136/jnnp.68.4.479">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1736897">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d6625e2741 class=n-a></a>Gultekin SH, Rosenfeld MR, Voltz R, <i> et al.</i>: Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. <i>Brain.</i> 2000; <b>123</b>(Pt 7): 1481–94. <a target=xrefwindow id=d6625e2752 href="http://www.ncbi.nlm.nih.gov/pubmed/10869059">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2755 href="https://doi.org/10.1093/brain/123.7.1481">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d6625e2764 class=n-a></a>Dalmau J, Graus F, Villarejo A, <i> et al.</i>: Clinical analysis of anti-Ma2-associated encephalitis. <i>Brain.</i> 2004; <b>127</b>(Pt 8): 1831–44. <a target=xrefwindow id=d6625e2775 href="http://www.ncbi.nlm.nih.gov/pubmed/15215214">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2778 href="https://doi.org/10.1093/brain/awh203">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d6625e2787 class=n-a></a>Greenlee JE, Boyden JW, Pingree M, <i> et al.</i>: Antibody types and IgG subclasses in paraneoplastic neurological syndromes. <i>J Neurol Sci.</i> 2001; <b>184</b>(2): 131–7. <a target=xrefwindow id=d6625e2798 href="http://www.ncbi.nlm.nih.gov/pubmed/11239946">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2801 href="https://doi.org/10.1016/s0022-510x(01)00442-7">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735597361"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2810 class=n-a></a>van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, <i> et al.</i>: The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. <i>Brain.</i> 2019; <b>142</b>(6): 1631–43. <a target=xrefwindow id=d6625e2821 href="http://www.ncbi.nlm.nih.gov/pubmed/31009048">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2824 href="https://doi.org/10.1093/brain/awz094">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2828 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6536844">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735597361">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d6625e2841 class=n-a></a>Höftberger R, van Sonderen A, Leypoldt F, <i> et al.</i>: Encephalitis and AMPA receptor antibodies: Novel findings in a case series of 22 patients. <i>Neurology.</i> 2015; <b>84</b>(24): 2403–12. <a target=xrefwindow id=d6625e2852 href="http://www.ncbi.nlm.nih.gov/pubmed/25979696">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2855 href="https://doi.org/10.1212/WNL.0000000000001682">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2859 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4478035">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d6625e2869 class=n-a></a>Irani SR, Vincent A: Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes. <i>Handb Clin Neurol.</i> 2016; <b>133</b>: 185–97. <a target=xrefwindow id=d6625e2877 href="http://www.ncbi.nlm.nih.gov/pubmed/27112678">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2880 href="https://doi.org/10.1016/B978-0-444-63432-0.00011-6">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727180877"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e2889 class=n-a></a>McKeon A, Tracy JA: GAD65 neurological autoimmunity. <i>Muscle Nerve.</i> 2017; <b>56</b>(1): 15–27. <a target=xrefwindow id=d6625e2897 href="http://www.ncbi.nlm.nih.gov/pubmed/28063151">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2900 href="https://doi.org/10.1002/mus.25565">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727180877">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d6625e2913 class=n-a></a>Bataller L, Galiano R, García-Escrig M, <i> et al.</i>: Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. <i>Neurology.</i> 2010; <b>74</b>(3): 265–7. <a target=xrefwindow id=d6625e2924 href="http://www.ncbi.nlm.nih.gov/pubmed/20083804">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2927 href="https://doi.org/10.1212/WNL.0b013e3181cb3e52">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2931 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2809037">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d6625e2940 class=n-a></a>Bataller L, Kleopa KA, Wu GF, <i> et al.</i>: Autoimmune limbic encephalitis in 39 patients: Immunophenotypes and outcomes. <i>J Neurol Neurosurg Psychiatry.</i> 2006; <b>78</b>(4): 381–5. <a target=xrefwindow id=d6625e2951 href="http://www.ncbi.nlm.nih.gov/pubmed/16980333">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2954 href="https://doi.org/10.1136/jnnp.2006.100644">Publisher Full Text </a> | <a target=xrefwindow id=d6625e2958 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2077770">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d6625e2967 class=n-a></a>Dorresteijn LDA, Kappelle AC, Renier WO, <i> et al.</i>: Anti-amphiphysin associated limbic encephalitis: A paraneoplastic presentation of small-cell lung carcinoma. <i>J Neurol.</i> 2002; <b>249</b>(9): 1307–8. <a target=xrefwindow id=d6625e2978 href="http://www.ncbi.nlm.nih.gov/pubmed/12242559">PubMed Abstract </a> | <a target=xrefwindow id=d6625e2981 href="https://doi.org/10.1007/s00415-002-0677-5">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d6625e2990 class=n-a></a>Gagnon MM, Savard M: Limbic Encephalitis Associated With GAD65 Antibodies: Brief Review of the Relevant literature. <i>Can J Neurol Sci.</i> 2016; <b>43</b>(4): 486–93. <a target=xrefwindow id=d6625e2998 href="http://www.ncbi.nlm.nih.gov/pubmed/27030381">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3001 href="https://doi.org/10.1017/cjn.2016.13">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d6625e3011 class=n-a></a>Saiz A, Bruna J, Stourac P, <i> et al.</i>: Anti-Hu-associated brainstem encephalitis. <i>J Neurol Neurosurg Psychiatry.</i> 2009; <b>80</b>(4): 404–7. <a target=xrefwindow id=d6625e3022 href="http://www.ncbi.nlm.nih.gov/pubmed/19015226">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3025 href="https://doi.org/10.1136/jnnp.2008.158246">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d6625e3034 class=n-a></a>Blaes F: Paraneoplastic Brain Stem Encephalitis. <i>Curr Treat Options Neurol.</i> 2013; <b>15</b>(2): 201–9. <a target=xrefwindow id=d6625e3042 href="http://www.ncbi.nlm.nih.gov/pubmed/23378230">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3045 href="https://doi.org/10.1007/s11940-013-0221-1">Publisher Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d6625e3054 class=n-a></a>Desai J, Mitchell WG: Acute cerebellar ataxia, acute cerebellitis, and opsoclonus-myoclonus syndrome. <i>J Child Neurol.</i> 2012; <b>27</b>(11): 1482–8. <a target=xrefwindow id=d6625e3062 href="http://www.ncbi.nlm.nih.gov/pubmed/22805251">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3065 href="https://doi.org/10.1177/0883073812450318">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d6625e3074 class=n-a></a>Armangué T, Sabater L, Torres-Vega E, <i> et al.</i>: Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. <i>JAMA Neurol.</i> 2016; <b>73</b>(4): 417–24. <a target=xrefwindow id=d6625e3085 href="http://www.ncbi.nlm.nih.gov/pubmed/26856612">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3088 href="https://doi.org/10.1001/jamaneurol.2015.4607">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3092 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5823978">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d6625e3101 class=n-a></a>Bataller L, Graus F, Saiz A, <i> et al.</i>: Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. <i>Brain.</i> 2001; <b>124</b>(Pt 2): 437–43. <a target=xrefwindow id=d6625e3112 href="http://www.ncbi.nlm.nih.gov/pubmed/11157570">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3115 href="https://doi.org/10.1093/brain/124.2.437">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d6625e3124 class=n-a></a>Blaes F, Pike MG, Lang B: Autoantibodies in childhood opsoclonus-myoclonus syndrome. <i>J Neuroimmunol.</i> 2008; <b>201-202</b>: 221–6. <a target=xrefwindow id=d6625e3132 href="http://www.ncbi.nlm.nih.gov/pubmed/18687475">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3135 href="https://doi.org/10.1016/j.jneuroim.2008.05.033">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736117143"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e3145 class=n-a></a>Mandel-Brehm C, Dubey D, Kryzer TJ, <i> et al.</i>: Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. <i>N Engl J Med.</i> 2019; <b>381</b>(1): 47–54. <a target=xrefwindow id=d6625e3156 href="http://www.ncbi.nlm.nih.gov/pubmed/31269365">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3159 href="https://doi.org/10.1056/NEJMoa1816721">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3163 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6800027">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736117143">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d6625e3176 class=n-a></a>Forsyth PA, Dalmau J, Graus F, <i> et al.</i>: Motor neuron syndromes in cancer patients. <i>Ann Neurol.</i> 1997; <b>41</b>(6): 722–30. <a target=xrefwindow id=d6625e3187 href="http://www.ncbi.nlm.nih.gov/pubmed/9189033">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3190 href="https://doi.org/10.1002/ana.410410608">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d6625e3199 class=n-a></a>Flanagan EP, McKeon A, Lennon VA, <i> et al.</i>: Paraneoplastic isolated myelopathy: Clinical course and neuroimaging clues. <i>Neurology.</i> 2011; <b>76</b>(24): 2089–95. <a target=xrefwindow id=d6625e3210 href="http://www.ncbi.nlm.nih.gov/pubmed/21670438">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3213 href="https://doi.org/10.1212/WNL.0b013e31821f468f">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737433096"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e3222 class=n-a></a>Dericioglu N, Gocmen R, Tan E: Paraneoplastic striatal encephalitis and myelitis associated with anti-CV2/CRMP-5 antibodies in a patient with small cell lung cancer. <i>Clin Neurol Neurosurg.</i> 2018; <b>170</b>: 117–9. <a target=xrefwindow id=d6625e3230 href="http://www.ncbi.nlm.nih.gov/pubmed/29777943">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3233 href="https://doi.org/10.1016/j.clineuro.2018.05.010">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737433096">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d6625e3246 class=n-a></a>Leypoldt F, Eichhorn P, Saager C, <i> et al.</i>: Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis. <i>J Neurol Neurosurg Psychiatry.</i> 2006; <b>77</b>(10): 1199–200. <a target=xrefwindow id=d6625e3257 href="http://www.ncbi.nlm.nih.gov/pubmed/16980662">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3260 href="https://doi.org/10.1136/jnnp.2005.086140">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2077551">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d6625e3273 class=n-a></a>Flanagan EP, Keegan BM: Paraneoplastic myelopathy. <i>Neurol Clin.</i> 2013; <b>31</b>(1): 307–18. <a target=xrefwindow id=d6625e3281 href="http://www.ncbi.nlm.nih.gov/pubmed/23186906">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3284 href="https://doi.org/10.1016/j.ncl.2012.09.001">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d6625e3294 class=n-a></a>Rudnicki SA, Dalmau J: Paraneoplastic syndromes of the spinal cord, nerve, and muscle. <i>Muscle Nerve.</i> 2000; <b>23</b>(12): 1800–18. <a target=xrefwindow id=d6625e3302 href="http://www.ncbi.nlm.nih.gov/pubmed/11102903">PubMed Abstract </a> | <a target="xrefwindow" id="d6625e3305" href="https://doi.org/10.1002/1097-4598(200012)23:12<1800::aid-mus3&gt;3.0.co;2-x">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d6625e3314 class=n-a></a>Chalk CH, Windebank AJ, Kimmel DW, <i> et al.</i>: The Distinctive Clinical Features of Paraneoplastic Sensory Neuronopathy. <i>Can J Neurol Sci.</i> 1992; <b>19</b>(3): 346–51. <a target=xrefwindow id=d6625e3325 href="http://www.ncbi.nlm.nih.gov/pubmed/1393844">PubMed Abstract </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d6625e3334 class=n-a></a>Dalmau J, Graus F, Rosenblum MK, <i> et al.</i>: Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. <i>Medicine (Baltimore).</i> 1992; <b>71</b>(2): 59–72. <a target=xrefwindow id=d6625e3345 href="http://www.ncbi.nlm.nih.gov/pubmed/1312211">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3348 href="https://doi.org/10.1097/00005792-199203000-00001">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d6625e3357 class=n-a></a>Camdessanché JP, Antoine JC, Honnorat J, <i> et al.</i>: Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. <i>Brain.</i> 2002; <b>125</b>(Pt 1): 166–75. <a target=xrefwindow id=d6625e3368 href="http://www.ncbi.nlm.nih.gov/pubmed/11834602">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3371 href="https://doi.org/10.1093/brain/awf006">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d6625e3380 class=n-a></a>Lauria G, Pareyson D, Sghirlanzoni A: Neurophysiological diagnosis of acquired sensory ganglionopathies. <i>Eur Neurol.</i> 2003; <b>50</b>(3): 146–52. <a target=xrefwindow id=d6625e3388 href="http://www.ncbi.nlm.nih.gov/pubmed/14530620">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3391 href="https://doi.org/10.1159/000073055">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d6625e3400 class=n-a></a>Gwathmey KG: Sensory neuronopathies. <i>Muscle Nerve.</i> 2016; <b>53</b>(1): 8–19. <a target=xrefwindow id=d6625e3408 href="http://www.ncbi.nlm.nih.gov/pubmed/26467754">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3411 href="https://doi.org/10.1002/mus.24943">Publisher Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d6625e3421 class=n-a></a>Graus F, Keime-Guibert F, Reñe R, <i> et al.</i>: Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. <i>Brain.</i> 2001; <b>124</b>(Pt 6): 1138–48. <a target=xrefwindow id=d6625e3432 href="http://www.ncbi.nlm.nih.gov/pubmed/11353730">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3435 href="https://doi.org/10.1093/brain/124.6.1138">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732392564"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e3444 class=n-a></a>Dubey D, Pittock SJ, Kelly CR, <i> et al.</i>: Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. <i>Ann Neurol.</i> 2018; <b>83</b>(1): 166–77. <a target=xrefwindow id=d6625e3455 href="http://www.ncbi.nlm.nih.gov/pubmed/29293273">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3458 href="https://doi.org/10.1002/ana.25131">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3462 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6011827">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732392564">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d6625e3475 class=n-a></a>Dalmau J, Geis C, Graus F: Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. <i>Physiol Rev.</i> 2017; <b>97</b>(2): 839–87. <a target=xrefwindow id=d6625e3483 href="http://www.ncbi.nlm.nih.gov/pubmed/28298428">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3486 href="https://doi.org/10.1152/physrev.00010.2016">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3489 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5539405 ">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d6625e3498 class=n-a></a>Titulaer MJ, Soffietti R, Dalmau J, <i> et al.</i>: Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. <i>Eur J Neurol.</i> 2011; <b>18</b>(1): 19–e3. <a target=xrefwindow id=d6625e3509 href="http://www.ncbi.nlm.nih.gov/pubmed/20880069">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3512 href="https://doi.org/10.1111/j.1468-1331.2010.03220.x">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3516 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3086523">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726172829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e3525 class=n-a></a>Graus F, Titulaer MJ, Balu R, <i> et al.</i>: A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurol.</i> 2016; <b>15</b>(4): 391–404. <a target=xrefwindow id=d6625e3536 href="http://www.ncbi.nlm.nih.gov/pubmed/26906964">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3539 href="https://doi.org/10.1016/S1474-4422(15)00401-9">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5066574">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726172829">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d6625e3556 class=n-a></a>Mann AP, Grebenciucova E, Lukas RV: Anti-<i>N</i>-methyl-D-aspartate-receptor encephalitis: Diagnosis, optimal management, and challenges. <i>Ther Clin Risk Manag.</i> 2014; <b>10</b>: 517–25. <a target=xrefwindow id=d6625e3567 href="http://www.ncbi.nlm.nih.gov/pubmed/25061311">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3570 href="https://doi.org/10.2147/TCRM.S61967">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3574 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4085332">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d6625e3584 class=n-a></a>Cortese I, Cornblath DR: Therapeutic plasma exchange in neurology: 2012. <i>J Clin Apher.</i> 2013; <b>28</b>(1): 16–9. <a target=xrefwindow id=d6625e3592 href="http://www.ncbi.nlm.nih.gov/pubmed/23420591">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3595 href="https://doi.org/10.1002/jca.21266">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3598 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3615701">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d6625e3607 class=n-a></a>Widdess-Walsh P, Tavee JO, Schuele S, <i> et al.</i>: Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. <i>J Neurooncol.</i> 2003; <b>63</b>(2): 187–90. <a target=xrefwindow id=d6625e3618 href="http://www.ncbi.nlm.nih.gov/pubmed/12825823">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3621 href="https://doi.org/10.1023/a:1023931501503">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726260381"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d6625e3630 class=n-a></a>Lee WJ, Lee ST, Byun JI, <i> et al.</i>: Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. <i>Neurology.</i> 2016; <b>86</b>(18): 1683–91. <a target=xrefwindow id=d6625e3641 href="http://www.ncbi.nlm.nih.gov/pubmed/27037228">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3644 href="https://doi.org/10.1212/WNL.0000000000002635">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726260381">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d6625e3657 class=n-a></a>Thöne J, Hohaus A, Lamprecht S, <i> et al.</i>: Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration. <i>J Neurol Sci.</i> 2008; <b>272</b>(1–2): 171–3. <a target=xrefwindow id=d6625e3668 href="http://www.ncbi.nlm.nih.gov/pubmed/18632117">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3671 href="https://doi.org/10.1016/j.jns.2008.04.020">Publisher Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d6625e3680 class=n-a></a>de Beukelaar JW, Sillevis Smitt PA: Managing paraneoplastic neurological disorders. <i>Oncologist.</i> 2006; <b>11</b>(3): 292–305. <a target=xrefwindow id=d6625e3688 href="http://www.ncbi.nlm.nih.gov/pubmed/16549814">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3691 href="https://doi.org/10.1634/theoncologist.11-3-292">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d6625e3700 class=n-a></a>Stark E, Wurster U, Patzold U, <i> et al.</i>: Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. <i>Arch Neurol.</i> 1995; <b>52</b>(8): 814–8. <a target=xrefwindow id=d6625e3711 href="http://www.ncbi.nlm.nih.gov/pubmed/7639633">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3714 href="https://doi.org/10.1001/archneur.1995.00540320098016">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d6625e3724 class=n-a></a>Vernino S, O'Neill BP, Marks RS, <i> et al.</i>: Immunomodulatory treatment trial for paraneoplastic neurological disorders. <i>Neuro-oncology.</i> 2004; <b>6</b>(1): 55–62. <a target=xrefwindow id=d6625e3735 href="http://www.ncbi.nlm.nih.gov/pubmed/14769141">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3738 href="https://doi.org/10.1215/S1152851703000395">Publisher Full Text </a> | <a target=xrefwindow id=d6625e3742 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1871966">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d6625e3751 class=n-a></a>Shams'ili S, Grefkens J, de Leeuw B, <i> et al.</i>: Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. <i>Brain.</i> 2003; <b>126</b>(Pt 6): 1409–18. <a target=xrefwindow id=d6625e3762 href="http://www.ncbi.nlm.nih.gov/pubmed/12764061">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3765 href="https://doi.org/10.1093/brain/awg133">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d6625e3774 class=n-a></a>Graus F, Abos J, Roquer J, <i> et al.</i>: Effect of plasmapheresis on serum and CSF autoantibody levels in CNS paraneoplastic syndromes. <i>Neurology.</i> 1990; <b>40</b>(10): 1621–3. <a target=xrefwindow id=d6625e3785 href="http://www.ncbi.nlm.nih.gov/pubmed/2215957">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3788 href="https://doi.org/10.1212/wnl.40.10.1621">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d6625e3797 class=n-a></a>Esposito M, Penza P, Orefice G, <i> et al.</i>: Successful treatment of paraneoplastic cerebellar degeneration with Rituximab. <i>J Neurooncol.</i> 2008; <b>86</b>(3): 363–4. <a target=xrefwindow id=d6625e3808 href="http://www.ncbi.nlm.nih.gov/pubmed/17924058">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3811 href="https://doi.org/10.1007/s11060-007-9479-z">Publisher Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d6625e3820 class=n-a></a>Vedeler CA, Antoine JC, Giometto B, <i> et al.</i>: Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. <i>Eur J Neurol.</i> 2006; <b>13</b>(7): 682–90. <a target=xrefwindow id=d6625e3831 href="http://www.ncbi.nlm.nih.gov/pubmed/16834698">PubMed Abstract </a> | <a target=xrefwindow id=d6625e3834 href="https://doi.org/10.1111/j.1468-1331.2006.01266.x">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 06 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-167&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-167&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Neurology, University of Utah, Salt Lake City, UT, 84108, USA<br/> <sup>2</sup> 2. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, 84148, USA<br/> <p> <div class=margin-bottom> Jonathan Galli <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> John Greenlee <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-167/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 06 Mar 2020, 9:167 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21309.1">https://doi.org/10.12688/f1000research.21309.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Galli J and Greenlee J. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=23466 data-id=21309 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21309.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-167/v1/pdf?article_uuid=fdc30eb4-44b8-4e09-8897-39dbb14573df" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21309.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Galli J and Greenlee J. Paraneoplastic Diseases of the Central Nervous System [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):167 (<a href="https://doi.org/10.12688/f1000research.21309.1" target=_blank>https://doi.org/10.12688/f1000research.21309.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21309 id=mobile-track-article-signin-21309 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21309?target=/articles/9-167"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=23466 /> <input name=articleId type=hidden value=21309 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Francesc Graus</strong>, Neuroimmunology Programme, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jerome Honnorat</strong>, Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon, Université Claude Bernard Lyon, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 06 Mar 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-167&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-167&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=64849-60817></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=64848-60816></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-167/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>06 Mar 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Francesc Graus</strong>, Neuroimmunology Programme, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jerome Honnorat</strong>, Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon, Université Claude Bernard Lyon, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-167&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-167/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Paraneoplastic Diseases of the Central Nervous...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-167/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-167/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-167/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Galli J and Greenlee J');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-167/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-167",
            templates : {
                twitter : "Paraneoplastic Diseases of the Central Nervous System. Galli J and Greenlee J, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-167/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Paraneoplastic Diseases of the Central Nervous System", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Paraneoplastic Diseases of the Central Nervous System", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21309/23466")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "23466");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "60816": 1,
                           "60817": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "99ce6d86-27e3-44c2-a550-37ff0bb64d0b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-167.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-167.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-167.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-167.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-167.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>